FOXP3 and neoplasm: There was a slight increasein the proportion of cases with FOXP3 expression in the tumor cells aftertreatment; 32% of cases treated with neoadjuvant ADT and RT showed FOXP3 tumorcell positivity, compared to 17% of untreated cases (Table 3).